Redbiotec closes deal with Merck
Redbiotec is pleased to announce that it has entered into collaboration with Merck Sharp & Dohme Corp. (NJ, USA), in which it will apply its proprietary technology platform rePAX® to an undisclosed discovery area.
With this agreement, Redbiotec further strengthens its customer base, after recent deals with Roche in December 2010 and the closing of a perennial collaboration agreement with an undisclosed big pharma partner in July 2011.
Redbiotec develops prophylactic vaccines in the area of CMV (Cytomegalovirus), HPV and Influenza and provides customized solutions in biologics.